Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

DR-01

Phase 2Small molecule

DR-01 is one of 79 small molecule programs targeting Leukemia. It is currently in Phase 2.

3

Indications

4

Total Trials

3

Active Trials

78

Competitors

Pipeline

Status by Indication[3][1]

Indication

LeukemiaRecruiting

Alopecia AreataActive, not recruiting

Bone Marrow Failure SyndromesNot yet recruiting

LeukemiaPhase 2

Recruiting

Alopecia AreataPhase 1

Active, not recruiting

Bone Marrow Failure SyndromesPreclinical

Not yet recruiting

Competition

Competitive Landscape

108 competitors in Leukemia

#DrugCompanyPhaseTrials

Cytosar

Trexall

Jazz Pharmaceuticals

Fludara

Rituxan

Cytoxan

BBaxter Healthcare Corporation

Adriamycin

Oncovin

Vepesid

Decadron

AAspen Global Incorporated

Mesnex

BBaxter Healthcare Corporation

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Leukemia

NCT05475925

Q2 2027

Phase 1Active, not recruiting

Alopecia Areata

NCT06602232

Q4 2030

PreclinicalRecruiting

Bone Marrow Failure Syndromes

NCT07712562

Clinical

Trials by Indication[1]

Leukemia1 trial

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

Recruiting·DDren Bio·Phase 1/2·NCT05475925·69 enrolled

Bone Marrow Failure Syndromes1 trial

A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Dibotatug in Adults With Bone Marrow Failure Syndromes

Recruiting·DDren Bio·Preclinical·NCT07712562·60 enrolled

Alopecia Areata1 trial

A Pilot, Safety and Clinical Activity, Phase 1b Study of DR-01 in Adults With Alopecia Areata or Vitiligo

Active, not recruiting·DDren Bio·Phase 1·NCT06602232·81 enrolled

Unspecified1 trial

A Study of Subcutaneous DR-01 in Healthy Volunteers

Completed·DDren Bio·Phase 1·NCT06766864·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for DR-01. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DR-01 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DR-01. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dren Bio company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: DDren Bio

Related News